GEA
ACAD icon

Glen Eagle Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Glen Eagle Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-30
Closed -$903 – 680
2017
Q4 		$903 Hold
30
– – ﹤0.01% 610
2017
Q3 		$1.13K Hold
30
– – ﹤0.01% 609
2017
Q2 		$837 Buy
+30
New +$894 ﹤0.01% 569

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Glen Eagle Advisors's ACAD Position: Q1 2018 in Review

Glen Eagle Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q1 2018, closing a stake of 30 shares — an estimated $903 sold.

Glen Eagle Advisors first reported a position in ACAD in Q2 2017 and held it in 3 quarters. The position peaked at $1.13K in Q3 2017. 196 funds tracked by Wall St. Rank hold ACAD as of Q1 2018.

  • Glen Eagle Advisors reported no remaining Acadia Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Glen Eagle Advisors sold 30 Acadia Pharmaceuticals shares in Q1 2018, an estimated $903.
  • Glen Eagle Advisors first reported a position in Acadia Pharmaceuticals in Q2 2017 and held it in 3 quarters.
  • Glen Eagle Advisors's Acadia Pharmaceuticals position peaked at $1.13K in Q3 2017.
  • 196 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2018.

Based on Glen Eagle Advisors's 13F filing for Q1 2018, filed 13 Aug 2024.